

- | | |
|----------------------|---------------------|
| Abraham, N.G. 67, 82 | Ildstad, S.T. 78 |
| Acholonu, I.N. 78 | Kelsey, L.S. 97 |
| Ahmed, T. 82 | Knazek, R.A. 106 |
| Bergheim, M. 78 | Maneval, D.C. 97 |
| Blaese, R.M. 89, 106 | Mueller, Y.M. 78 |
| Candotti, F. 89, 106 | Nelson, D.M. 89 |
| Exner, B.G. 78 | Onodera, M. 89, 106 |
| Farley, T. 82 | Sabaawy, H.E. 82 |
| Feldman, E. 82 | Sakiyama, Y. 89 |
| Hirai, M. 97 | Talmadge, J.E. 97 |
| Ikehara, S. 68 | Vaillancourt, M. 97 |

Subject Index Vol. 101, No. 2, 1999

- | | |
|---|---|
| Adenovirus 97 | Mixed allogeneic chimerism 78 |
| Allogeneic bone marrow transplantation 68 | Organ allograft 68 |
| Autoimmune diseases 68 | p53 97 |
| Bone marrow transplantation 78 | Portal venous injection 68 |
| Breast cancer 97 | Purging 97 |
| Clonogenic growth 97 | Retroviral vector 89, 106 |
| Colon cancer 82 | Severe combined immunodeficiency,
adenosine deaminase 89 |
| Facilitating cell 78 | Stem cells, hematopoietic 89 |
| 5-Fluorouracil 82 | T lymphocytes, peripheral 89 |
| Gene therapy 89, 106 | Tolerance 78 |
| – transfer 82 | XSCID 106 |
| Hematopoietic progenitors 106 | |
| Interferon- α 82 | |